Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg.24-02-2023
24-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
The Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on February 22, 2023.22-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Releases20-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Sirolimus Tablets, 1 mg and 2 mg17-02-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201516-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Canagliflozin Tablets15-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension15-02-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201514-02-2023
Zydus Lifesciences Ltd - 532321 - Investor Conference
The Company will be participating in IIFL's 14th Enterprising India Global Investors' Conference at Mumbai on February 15, 2023.11-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Post Results Earnings Call held on February 3, 202310-02-2023